SCHEMBL68773

SCHEMBL68773

O=C1CCC2CC=CC=C2N1

nearest known ligand 0.33

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 18/20 0.33
DDB1 Q16531 17/20 0.33
IKZF3 Q9UKT9 2/20 0.32
ALDH1A1 P00352 1/20 0.30
CHRM2 P08172 1/20 0.30
OPRM1 P35372 1/20 0.30
CYP1A2 P05177 1/20 0.30
TSHR P16473 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33371399 1.00 CRBN (0.33) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL6196078 0.89 CRBN (0.35) CRBN
SCHEMBL2138420 0.88 CRBN (0.34) CRBN
SCHEMBL2082342 0.82
SCHEMBL421623 0.81 CRBN (0.32) CRBN
Benzotriazole SCHEMBL17653903 0.79 CRBN (0.35) CRBNDDB1IKZF3
SCHEMBL31236837 0.78
SCHEMBL6222418 0.78
SCHEMBL10555085 0.74
SCHEMBL28693337 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117695281-B Application of tetrahydroquinolinone-amide-thiazole compound 广州医科大学 2024-06-21 CN claimed
CN-117695281-A Application of tetrahydroquinolinone-amide-thiazole compound 广州医科大学 2024-03-15 CN claimed
WO-2022214520-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2022-10-13 WO claimed
WO-2022214519-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2022-10-13 WO claimed
CN-111732538-A Tetrahydroquinolinone derivative compounds and application thereof 南京百鑫愉医药有限公司 2020-10-02 CN claimed
US-20200283391-A1 Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases THE UNIVERSITY OF CHICAGO 2020-09-10 US claimed
CN-101657440-B Heterodimers and methods of use thereof BIOTECHNOLOGY RESEARCH Corp.,Ltd. (CN) 2016-01-13 CN claimed
WO-2012139876-A1 ENTERIC FORMULATIONS OF METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-18 WO claimed
CN-101657440-A Heterodimers and methods of use thereof BIOTECHNOLOGY RES CORP LTD HK 2010-02-24 CN claimed
US-7605265-B2 Heterodimers and methods of using them Biotechnology Research Corporation Ltd. (CN) 2009-10-20 US claimed
WO-2007050697-A2 COMPOSITIONS AND METHODS FOR THE ADMINISTRATION PSYCHOTROPIC DRUGS WHICH MODULATE BODY WEIGHT AZUR PHARMA III LIMITED (BM) 2007-05-03 WO claimed
US-20070093471-A1 Compositions and methods for the administration clozapine formulations which modulate body weight ALAMO PHARMACEUTICALS, LLC (US) 2007-04-26 US claimed
EP-1730145-A1 ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-12-13 EP claimed
CN-1735599-A 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands BOEHRINGER INGELHEIM PHARMA (US) 2006-02-15 CN claimed
US-20050234091-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-10-20 US claimed
WO-2005095401-A1 ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-10-13 WO claimed
EP-1583745-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-10-12 EP claimed
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-08-19 US claimed
WO-2004063163-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-07-29 WO claimed
CN-1038640-A Two ring carboxamide, its preparation methods and contain the pharmaceutical composition of this material BOEHRINGER MANNHEIM GMBH (DE) 1990-01-10 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283391-A1 Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases TUBB1, MYADM, TUBB CRBN 3793/4885DDB1 1245/4885IKZF3 2248/4885
US-20050234091-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof NR3C1, MC2R, NR3C2 CRBN 1884/4885DDB1 3427/4885IKZF3 3080/4885
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof NR3C1, NR3C2, MC2R CRBN 2591/4885DDB1 3428/4885IKZF3 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.